Vizora日本語

Wakamoto PharmaceuticalWAKAMOTO PHARMACEUTICAL CO.,LTD.4512東証スタンダード医薬品FY ending Mar 2026, non-consolidated, J-GAAP

Wakamoto Pharmaceutical FY ending Mar 2020 results

About 60% of Wakamoto Pharmaceutical's sales come from Ethical products business-related, with Otc products business-Related and Sales Development business-Related making up much of the rest.

It lost about ¥9 for every ¥100 of sales at the operating level.

Where the money goes

Where ¥100 of sales goes

For every ¥100 Wakamoto Pharmaceutical sells, how much goes where, and how much is kept.

FY ending Mar 2020
Cost of sales
¥43
SG&A
¥66
Operating loss
¥9
Net loss
¥15

Margin funnel (derived from reported values)Gross margin 56.7% → Operating margin -9.1% → Net margin -15.2%

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2020

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (3)

  • EDINET (FSA Japan)

    有価証券報告書－第129期(2023/04/01－2024/03/31)

    ID S100TTRJ2024-06-28Open

  • EDINET (FSA Japan)

    有価証券報告書－第127期(令和3年4月1日－令和4年3月31日)

    ID S100OCE22022-06-24Open

  • EDINET (FSA Japan)

    有価証券報告書－第126期(令和2年4月1日－令和3年3月31日)

    ID S100LMJG2021-06-25Open

Extracted from XBRL: 39 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image